IRIXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends January 3

IRIDEX CORP

Financials through Q2 FY2026, quarter ended Jul 4, 2026Last filing: 10-Q on Aug 18, 2026

$0.77−0.04 (-5.48%)

Close on Oct 19, 2026

Market cap: $13.41M
P/E (TTM): –
Dividend yield: –

IRIDEX CORP income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2026-01-03	FY 2024 2024-12-28	FY 2023 2023-12-30	FY 2022 2022-12-31	FY 2021 2022-01-01	FY 2020 2021-01-02	FY 2019 2019-12-28	FY 2018 2018-12-29	FY 2017 2017-12-30	FY 2016 2016-12-31	FY 2015 2016-01-02	FY 2014 2015-01-03	FY 2013 2013-12-28	FY 2012 2012-12-29	FY 2011 2011-12-31	FY 2010 2011-01-01	FY 2009 2010-01-02
Revenue	53	49	52	57	54	36	43	43	42	46	42	43	38	34	33	32	31
Cost of Revenue	33	29	30	32	31	21	26	25	26	25	22	21	20	18	17	16	16
Gross Profit	19	20	22	25	23	16	18	17	16	21	20	21	19	16	16	16	15
Research & Development	3.67	5.45	6.83	7.18	6.87	3.28	3.68	4.01	5.21	5.37	5.21	4.63	3.68	4.39	3.91	3.75	3.32
Selling, General & Admin	18	22	25	26	23	19	23	26	23	18	14	14	13	13	12	11	11
Selling & Marketing	10	13	16	18	15	12	15	17	15	10	8.90	8.16	7.72	7.90	7.46	7.10	6.56
General & Administrative	7.73	9.78	8.75	7.56	8.86	6.62	8.38	9.55	8.78	7.64	5.55	6.03	5.02	4.93	4.26	4.16	4.34
Advertising Expenses	0.02	0.02	0.20	0.40	0.20	0.10	0.30	0.50	0.20	0.10	0.10	0.20	0.10	0.20	0.30	0.30	–
Operating Expenses	22	28	32	33	30	22	27	30	28	23	20	19	16	17	14	15	14
Operating Income	-2.57	-8.30	-10	-7.54	-7.53	-6.58	-8.97	-13	-13	-2.57	0.29	2.59	2.63	-0.86	1.93	1.19	1.23
Interest Expense	0.06	0.15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-1.81	-0.54	0.53	0.06	2.35	0.28	0.21	0.09	-0.11	-0.09	0.00	-1.26	-0.37	–	0.50	0.77	0.58
Asset Impairment Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	–
Gain (Loss) on Sale of Assets	–	–	–	0	0.00	-0.02	0.00	0.00	–	–	–	–	–	1.15	–	–	–
Legal Settlements	–	–	–	–	–	–	–	–	–	–	–	–	–	0.80	0.80	0.80	0.80
Pretax Income	-4.38	-8.84	-9.48	-7.48	-5.19	-6.30	-8.77	-13	-13	-2.66	0.29	1.33	2.26	-0.27	2.44	1.96	1.80
Income Tax Expense	0.06	0.07	0.09	0.07	0.04	0.03	0.05	0.04	-0.13	9.06	-0.18	-8.71	0.03	-0.10	0.30	0.31	0.26
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	–	10	2.23	-0.17	2.14	1.65	1.54
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	–	–	–	1.61	0.65	1.56	1.04
Net Income incl. Noncontrolling Interests	-4.44	-8.91	-9.57	-7.55	-5.23	-6.33	-8.81	-13	-13	–	–	–	–	–	–	–	–
Net Income	-4.44	-8.91	-9.57	-7.55	-5.23	-6.33	-8.81	-13	-13	-12	0.47	10	2.23	1.44	2.61	3.05	2.59
EPS (Basic)(per share)	-0.26	-0.54	-0.59	-0.47	-0.34	-0.46	-0.64	-1.05	-1.11	-1.15	0.05	1.01	0.24	0.16	0.29	0.34	–
EPS (Diluted)(per share)	-0.26	-0.54	-0.59	-0.47	-0.34	-0.46	-0.64	-1.05	-1.11	-1.15	0.05	0.97	0.22	0.16	0.26	0.30	–
Shares Outstanding (Basic, Weighted)(shares)	17	16	16	16	15	14	14	12	12	10	9.96	9.89	9.25	8.94	8.96	8.94	8.84
Shares Outstanding (Diluted, Weighted)(shares)	17	16	16	16	15	14	14	12	12	10	10	10	10	8.94	10	10	9.94
EBITDA	-2.05	-7.72	-8.91	-7.06	-6.73	-6.08	-8.29	-12	-12	-1.92	0.81	3.01	3.12	-0.43	2.34	1.49	1.67

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jul 4, 2026

Profitability, TTM

Gross margin: 35.9%
Operating margin: -5.4%
Net margin: -6.9%
Return on equity, FY2025: -126.4%

Financial strength

Current ratio: 1.82
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 35.5%

Valuation

P/E ratio: –
Price to sales: 0.26
Price to book: 3.69
Dividend yield: –